For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
2017 was a very good year for many of the agencies profiled in this annual directory featuring the leading healthcare communications agencies. Some reported individual setbacks, but they were still able to overcome these. As a wave of new drugs and biologics hit the market, several of the top healthcare agencies supported their launches.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
For many of the healthcare advertising agencies featured within this annual special report, 2016 was another year of growth and change. With the election of Donald Trump as president of the United States and the United Kingdom’s Brexit vote to exit the European Union, the year also introduced uncertainty to agencies and their clients.
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
Management from 2016 Manny Award winners and finalists weigh in on various industry topics presented to them by Med Ad News.
The amount of new drug approvals in 2015 was the FDA’s highest total since 1950 due in part to revamped pipelines, but a tough future looms as the grumblings over pricing have risen to a roar.
AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
Long-established healthcare communications agencies in 2015 saw their businesses expand, and relative newcomers continued to find their stride.